Beyond its previous evaluation in acute heart failure, serelaxin or next-generation RLN-2 analogs could be explored in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus, in fibrotic conditions including systemic sclerosis and chronic kidney disease, and in pregnancy-related complications such as preeclampsia. This evidence concerns the gene RLN2 and chronic kidney disease.